

Neoadjuvant chemotherapy in patients with locally advanced and /or nodal positive gastric cancer with Docetaxel, Cisplatin and 5-FU

Submission date 27/07/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 18/10/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/09/2016	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Gastric cancer is a fairly uncommon type of cancer that develops from the lining of the stomach. Cancer that begins in the stomach and spreads to another part of the body or comes back after treatment is termed advanced stomach cancer. Despite the use of aggressive chemotherapies (medicines that stop cancer cells from dividing and multiplying), the outlook for patients with advanced gastric cancer is rather poor. Even after radical surgery, the overall 5-year survival rate is 20 – 30 % in Europe. Chemotherapy can be given before surgery to try to shrink the tumour so it may then be easier to remove. This type of treatment is called neoadjuvant chemotherapy. The aim of this study is to assess the effectiveness and toxicity (side effects) of neoadjuvant chemotherapy with the drugs docetaxel, cisplatin and 5-FU.

Who can participate?

Patients aged 18 and older with advanced gastric cancer

What does the study involve?

Chemotherapy treatment is given in three cycles, which start on days 1, 22 and 43. For safety monitoring, blood samples are taken on a weekly basis, heart activity is monitored and side effects are recorded. Participants are assessed to see whether the cancer can be fully removed in surgery (curative resection). Side effects and quality of life are also assessed to measure the impact of the disease and chemotherapy on daily life.

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

Medical University of Greifswald (Germany)

When is the study starting and how long is it expected to run for?

September 2007 to February 2012

Who is funding the study?
Medical University of Greifswald (Germany)

Who is the main contact?
Prof. Julia Mayerle

Contact information

Type(s)
Scientific

Contact name
Prof Julia Mayerle

Contact details
Medical University of Greifswald
Department of Internal Medicine
Friedrich-Loeffler-Straße 23a
Greifswald
Germany
17475

Additional identifiers

Protocol serial number
23:07:2007

Study information

Scientific Title
Phase II trial for neoadjuvant chemotherapy in patients with locally advanced and /or nodal positive gastric cancer (UICC stages IIIa, IIIb and IV M0) with Docetaxel, Cisplatin and 5-FU

Acronym
NeoDox

Study objectives
A neoadjuvant chemotherapy in patients with advanced gastric cancer is expected to improve R0 surgical resection and therefore prolong survival of these patients

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics Committee at the Medical Faculty of the University of Greifswald [Ethikkommission an der Medizinischen Fakultät der Universität Greifswald], 26/02/2004, ref: III UV 10/04

Study design
Non-randomised open-label single-group interventional single-centre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Locally advanced and/or nodal positive gastric cancer (UICC Stages: IIIa, IIIb, IV M0)

Interventions

1. Docetaxel: 75 mg/m², (infusion, days 1, 22, 43)
2. Cisplatin: 75 mg/m², (infusion, days 1, 22, 43)
3. 5-FU: 750 mg/(m² x day), (infusion, days 1-5, 22-26, 43-47)

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Cisplatin, docetaxel, 5-FU

Primary outcome(s)

Rate of curative (R0) resections after a neoadjuvant chemotherapy

Key secondary outcome(s)

1. Median survival
2. Median progression-free survival
3. Remission rate
4. Toxicity of the protocol
5. Quality of life during neoadjuvant chemotherapy

Completion date

29/02/2012

Eligibility

Key inclusion criteria

1. Locally advanced and/or node positive gastric adenocarcinoma (UICC stages IIIa, IIIb, IV and M0)
2. Aged 18 years and older
3. Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0 - 2
4. Adequate organ function
5. Signed informed consent
6. Participants: patients of both genders, no healthy volunteers

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Metastatic disease
2. Prior chemotherapy for gastric cancer
3. Tumour recurrence after gastrectomy
4. Estimated life expectancy < 3 months
5. Presence of any serious concomitant systemic disorder

Date of first enrolment

01/09/2007

Date of final enrolment

29/02/2012

Locations**Countries of recruitment**

Germany

Study participating centre

Medical University of Greifswald

Greifswald

Germany

17475

Sponsor information**Organisation**

Medical University of Greifswald (Germany)

ROR

<https://ror.org/00r1edq15>

Funder(s)

Funder type

University/education

Funder Name

Medical University of Greifswald (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes